The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice
- 1 May 2005
- Vol. 23 (25), 3280-3287
- https://doi.org/10.1016/j.vaccine.2005.01.086
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) ImmunityClinical Cancer Research, 2005
- Immunological inhibition of carcinogenesisCancer Immunology, Immunotherapy, 2004
- Prophylactic cancer vaccinesCurrent Opinion in Immunology, 2002
- Insertion of the DNA for the 163–171 peptide of IL1β enables a DNA vaccine encoding p185neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c miceGene Therapy, 2001
- A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptorsOncogene, 1997
- Prevention of breast tumour development in vivo by downregulation of the p185neureceptorNature Medicine, 1995
- Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbb-2 (her-2/neu) gene product p185International Journal of Cancer, 1993
- Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogeneCell, 1988
- Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.Proceedings of the National Academy of Sciences, 1986
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985